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Abstract 
Objectives 
To determine if associations exist between pre-treatment dynamic contrast 
enhanced-MRI (DCE-MRI) based metrics (vascular kinetics, texture, shape, size) 
and survival intervals. Further, to compare the prognostic value of DCE-MRI 
parameters against traditional pre-treatment survival indicators.  
Materials and Methods 
A retrospective study was undertaken. Approval had previously been granted for the 
retrospective use of such data and the need for informed consent was waived. 
Prognostic value of pre-treatment DCE-MRI parameters and clinical data was 
assessed via Cox’s proportional hazards models (CPHM). The variables retained by 
the final overall survival CPHM were utilised to stratify risk of death within 5 years.  
Results 
One hundred and twelve subjects were entered into the analysis. Regarding disease 
free survival negative oestrogen receptor status, T3 or higher clinical tumour stage, 
large (>9.8cm3) MR tumour volume, higher 95th percentile (>79%) percentage 
enhancement and reduced (>0.22) circularity represented the retained model 
variables. Similar results were noted for the overall survival with negative oestrogen 
receptor status, T3 or higher clinical tumour stage, and large (>9.8cm3) MR tumour 
volume again all been retained by the model in addition to higher (>0.71) 25th 
percentile area under the enhancement curve. 
Accuracy of risk stratification based on either traditional (59%) or DCE-MRI (65%) 
survival indicators performed to a similar level. However, combined traditional and 
MR risk stratification resulted in the highest accuracy (86%). 
Conclusion 
Multivariate survival analysis has revealed that model retained DCE-MRI variables 
provide independent prognostic information complementing traditional survival 
indicators and as such could help to appropriately stratify treatment. 
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Introduction 
Neoadjuvant chemotherapy (NAC) has become the standard treatment for patients 
diagnosed with locally advanced breast cancer (LABC) and some large operable 
breast tumours prior to surgery and adjuvant therapies [1]. The objective of NAC is 
not simply to downstage the primary tumour, hopefully facilitating breast conserving 
surgery (BCS) [2], but also to eradicate distant micro-metastases [2]. For those 
patients undergoing NAC whom achieve a pathological complete response (pCR) a 
survival advantage has been reported [2, 3]. However, the response to NAC can be 
quite variable with the majority of patients not achieving pCR [4]. 
Presently, patients undergo treatment stratification based on traditional prognostic 
indicators such as disease stage and lesion descriptors [5]. However, following this 
strategy not only is the initial response to NAC variable but also the longer term 
survival [3].  
Researchers are currently trying to identify potential biomarkers to facilitate 
individualised treatments, and a number of investigators have identified dynamic 
contrast enhanced MRI (DCE-MRI) as a potential biomarker of longer term survival. 
DCE-MRI vascular kinetics reflect blood flow, vascular density and vessel 
permeability [6]. Literature reports have highlighted associations between DCE-MRI 
vascular kinetics obtained prior to and/or early (post 1st or 2nd NAC cycle) during 
NAC and survival intervals [7-19]. DCE-MRI data is processed by studying changes 
in the signal intensity against time to derive vascular parameters. However, the static 
source DCE-MRI images can also provide information related to both tumour texture 
and shape. Texture analysis results in the quantification of grey-level intensity and 
spatial variation thereby providing textural features that characterise the underlying 
structure of the object under investigation. Textural features have been previously 
described [20] and have been linked not only with traditional breast cancer 
prognostic indicators but also the initial response to NAC treatment [21]. Likewise 
tumour shape has also been associated with prognostic indicators [22]. We 
hypothesise that given the association with prognostic indicators that both texture 
and shape will also be associated with longer term survival along with DCE-MRI 
vascular kinetics. 
If suitable biomarkers could be identified that can predict survival outcome prior to 
NAC, then decisions regarding treatment stratification could be taken even before 
the initiation of NAC. Treatments with higher levels of side effects and/or increased 
post treatment surveillance could be justified in cases where patients were predicted 
to have shorter survival intervals.  
The aims of this study were to determine if any associations exist between pre-
treatment DCE-MRI based parameters (vascular kinetics, texture, shape) and 
survival intervals [disease free (DFS) and overall survival (OS)], additionally, to 
compare the prognostic value of DCE-MRI parameters against traditional survival 
indicators obtained prior to NAC. 
  
Materials and Methods 
Study population 
Patients scheduled for NAC are routinely referred to this Institute for breast MR 
examinations prior to treatment to facilitate baseline assessment of their disease. 
During the study period the NAC regime typically consisted of 4, three-weekly cycles 
of combined intravenous epirubicin (90 mg/m2) and cyclophosphamide (600 mg/m2) 
followed by four cycles of Docetaxel (100mg/m2). After successful down-staging of 
their disease patients underwent mastectomy or BCS. This initial treatment was 
followed by individually tailored adjuvant therapies.  
A survival study was undertaken of LABC patients and large operable breast cancers 
that had undergone neoadjuvant chemotherapy. Approval had previously been 
granted for the retrospective use of such data, as this activity did not involve any 
non-clinical research scans or the retrieval of non-clinical patient information, 
informed consent was not sought. Information held locally on a breast cancer 
database was used to retrospectively identify women who had undergone NAC 
between April 2006 and December 2009. To be included in the survival database 
patients must have undergone a pre-treatment breast MRI examination, received at 
least four cycles of NAC, proceeded to surgery and adjuvant radiotherapy. 
Traditional pre-treatment survival indicators were obtained from the results of pre-
treatment biopsies and clinical examinations via the hospital’s electronic note 
system. 
MRI technique 
All MR imaging was undertaken on a 3.0T scanner (GE Healthcare, Milwaukee, 
USA) in combination with the manufacture’s 8 channel phased array breast coil, prior 
to the initiation of NAC. In each case a DCE-MRI dataset was acquired utilising a 3 
dimensional sagittal T1W fat nulled VIBRANT (Volume Imaging for Breast 
Assessment) sequence with the following parameters: TR/TE/TI 4.1/1.6/5ms, flip 
angle 8°, FOV 22 x 22cm or 20 x 20cm,  slice/gap 4mm/0mm interpolated to 
2mm/0mm, matrix 220x160, bandwidth 41.7kHz, parallel imaging x2. Median 
temporal (min. max.) resolution was 33.1 (23.5, 44.7) seconds. 
 
At the start of the 3rd dynamic phase a bolus injection of gadolinium contrast agent 
(0.05 mmol/kg body weight) was delivered by a Spectris Solaris power injector 
(Medrad, Warrendale, PA, USA) immediately followed by a 20ml saline flush, total 
injection time 10 seconds for all patients. Between the start of the study period and 
July 2008 gadodiamide (Gd-DTPA-BMA, Omniscan, GE Healthcare, Olso, Norway) 
was utilised as the gadolinium containing contrast agent however from July 2008 
until the end of the study period gadoterate (Gd-DOTA, Dotarem, Paris, France) was 
used. The r1 relaxivity in plasma at 37°c for gadodiamide and gadoterate at 3.0T are 
reported to be 3.8-4.2 L mmol-1 s-1 and 3.3-3.7 L mmol-1 s-1 respectively [24]. 
 
All processing steps were undertaken by a researcher with ten years’ experience of 
breast MR analysis. Regions of interest and vascular kinetics were processed via 
software developed in-house utilising IDL language (Exelis Visual Information 
Solutions Inc., Boulder, CO, USA) to facilitate model free empirical analysis of the 
enhancement characteristics of the lesions. The analysis procedure is briefly 
outlined. Individual phases of the DCE-MRI dataset were visually inspected for 
significant motion related misalignment, if noted the subject was excluded from the 
analysis. Early arterial phase images (~ post 1 minute contrast injection) were 
interrogated to facilitate whole lesion segmentation. On each slice that demonstrated 
tumour a seed point was selected and an iterative semi-automated ROI was 
generated. If multiple tumour foci were noted on a slice then an ROI was generated 
for each focus. In this manner a 3-dimensional volume of interest was generated. For 
DCE-MRI analysis the signal intensity time course was assessed in a pixel-by-pixel 
manner across all dynamic phases. Linear interpolation was employed to determine 
vascular parameters. Histogram analysis of the whole lesion was undertaken to 
allow an assessment of tumour heterogeneity and resulted in first order statistics 
(mean, SD, skew, kurtosis, median and percentiles – 5th, 10th, 25th, 75th, 90th, 95th) 
for the following model free empirical parameters: 
 
1. EImax – The maximum enhancement index recorded during the experiment, 
 where enhancement index = St/S0 –1 
St is the signal at a given time and 
S0 represents the baseline signal. 
2. Tmax – Time to maximum, the time (seconds) to reach the maximum 
enhancement index from a manually defined start of the uptake curve 
3. Rise time (RT) – Time (seconds) to reach the half maximum enhancement 
index point from the start of the uptake curve.  
4. nMITR –Maximum intensity time ratio (MITR), normalised to the baseline 
signal.  
5. PC30 – Percentage of the maximum enhancement index recorded 30 seconds 
from the onset of the enhancement curve. 
6. Initial slope – Average gradient of the uptake curve between the start of the 
enhancement curve and 30 seconds later. 
7. Final slope – Average gradient over the last 120 seconds of the enhancement 
curve. 
8. AUC60 – Area under the enhancement curve at 60 seconds from the onset of 
enhancement. 
 
Texture and shape parameters were processed utilising MatLab (MathWorks, Natick, 
MA, USA). ROI data was imported from the DCE-MRI processing step. Texture 
analysis resulted in second order statistical features as outlined by Haralick et al. 
[20] (f1-f14) and Conners et al. [24] (f15 and f16) from the whole tumour ROI data for 
1 minute post-contrast injection images. To avoid data sparseness images were 
decimated via histogram equalisation to 16 grey levels. Co-occurrence matrices with 
a pixel distance of 1 were calculated along 0°, 45°, 90° and 135° and subsequently 
averaged, see Ahmed et al. [21] for more details. 
 
Given the through-plane spatial resolution it was felt that 3 dimensional shape 
analyses was inappropriate. Consequently, shape parameters, circularity [25], 
complexity [26] and convexity [26] were obtained from the individual ROI with the 
largest surface area.  
 
Finally, MRI based size parameters, longest dimension (LD) and volume, were 
determined from the ROI data and entered into the survival analysis. MR based 
processing steps are illustrated in Figure 1. 
 
Statistical Analysis 
Subjects were followed up for five years following NAC treatment. To obtain survival 
data a final review of patients’ electronic notes was undertaken in January 2015. 
Patients were categorised as having a critical survival event or censored. Critical 
events were defined as local tumour recurrence and/or metastasis (DFS) or a cancer 
related death (OS). Patients without critical events or lost to follow up, but known to 
be well at their most recent follow-up, were censored. The DFS and OS time interval 
was defined as the time from initiation of NAC to critical or censored event. 
 
Both traditional prognostic indicators and DCE-MRI parameters underwent univariate 
Cox’s proportional hazards model analysis. To facilitate survival analysis traditional 
prognostic indicators were dichotomised as follows: age (≤45years or >45 years), 
grade (I and II or III), histological type (special type or no special type), oestrogen 
receptor (ER) status (negative or positive), progesterone (PR) status (negative or 
positive), human epidermal growth factor receptor 2 (HER2) status (negative or 
positive), intrinsic subtype (triple negative or all other), T stage (≤T2 or >T2), and N 
stage (N0 or ≥N1). To allow appropriate dichotomisation of DCE-MRI parameters the 
Youden’s Index [27] was utilised to highlight a suitable threshold for each MR 
parameter. 
 
To allow an assessment of interactions between individual parameters a multivariate 
Cox’s proportional hazards model was employed. However, in an attempt to 
streamline the number of variables entered into the model, while allowing a 
comparison with all traditional prognostic indicators, only those MR parameters that 
demonstrated a significant (p ≤0.025) univariate results were subsequently entered 
into the multivariate model. By lowering the alpha level the number of MR 
parameters entered into the multivariate analysis was restricted in the hope of 
increasing model generalisation. 
 
Following the multivariate overall survival analysis retained variables were used to 
stratify risk of death within 5 years of initiation of NAC treatment. For each subject 
the individual hazard ratios (HR) were summed for two separate groups, traditional 
prognostic indicators and MR parameters. While for a third combined group 
(traditional plus MR) previously calculated hazard ratio scores were summed. To 
facilitate appropriate dichotomisation of the hazard ratio score the Youden’s Index 
[27] was utilised. Once dichotomised each group underwent Kaplan-Meier analysis. 
 
All statistical analyses were undertaken utilising IBM SPSS version 20.0 (New York, 
USA) and MedCalc version 12.1, MedCalc Software (Ostend Belgium).  
Results 
Following a review of the local breast cancer database 138 potential subjects were 
identified. However 26 cases were excluded for a variety of reasons; incomplete MR 
data (4); less than 4 cycles of NAC (3); did not proceed to surgery (11); did not 
undergo radiotherapy (5); changed from curative to palliative intent (2); and 
incomplete clinical data held locally (1). Table 1 presents the pre-treatment lesion 
characteristics, clinical and treatment information for the 112 subjects that were 
entered into the survival analysis. 
 
Regarding DFS, 29 critical events were noted and 83 subjects were censored. The 
median follow up interval for the whole DFS cohort was 60 months (min. 8, max. 60 
months). When considering OS, 24 cancer related deaths were recorded and 88 
patients were censored. The median follow up interval for the whole OS group was 
60 months (min. 12, max. 60 months). Table 2 presents the follow up intervals for 
critical and censored subjects for both DFS and OS. 
 
Univariate Cox proportional hazards model results for both traditional survival 
indicators and MRI parameters are presented in Table 3 and 4 respectively. 
Significant results for traditional survival indicators remained constant between the 
DFS and OS analysis with ER(-ve), PR(-ve), intrinsic subtype(triple negative), T stage(≥T3), 
and N stage(≥N1) status all resulting in increased hazard. T stage status resulted in 
the highest hazard ratio for both disease free and overall survival. The T stage status 
for OS resulted in a considerably higher hazard ratio compared to the other 
significant results, whereas for the DFS analysis T stage hazard ratio was only 
marginally higher than the other traditional indicators.  
The univariate results for MR parameters revealed significant results for size, 
vascular kinetic, texture and shape based metrics. Again consistent trends were 
noted between the disease free and overall survival results. Results for MR based 
tumour size indicators (longest dimension or volume) were associated with highly 
significant elevated hazard ratios. Whereas the maximum enhancement achieved 
(EImax), rate of enhancement (RT, PC30, and initial slope), and the amount of 
contrast agent delivered to and retained by the tumour over 60 seconds (AUC60) 
revealed significant hazard ratio results for vascular kinetics for both disease free 
and overall survival. Additionally, significant results were also noted for nMITR and 
final gradient when considering DFS and Tmax for the OS analysis. Texture features 
[f7 (sum variance), f8 (sum entropy), f15 (cluster shade) and f16 (cluster 
prominence)] were consistently associated with survival for both disease free and 
overall survival. When considering shape parameters complexity was identified as a 
significant measure for both disease free and overall survival while circularity and 
convexity were only significant for the disease free analysis. 
 
All traditional prognostic indicators along with significant (p≤0.025) univariate survival 
analysis DCE-MRI parameters were entered into multivariate models. To be entered 
into a model subjects had to have all necessary data. For six individuals at least one 
piece of information (e.g. histological grade) was unavailable consequently 106 
subjects were entered into the multivariate models. The results of the Cox’s 
proportional hazards models are presented in Tables 5 and 6 for DFS and OS 
respectively. When considering DFS negative ER receptor status (HR 2.08), T3 or 
higher clinical tumour stage (HR 2.34), large (>9.8cm3) MR tumour volume (HR 
4.93), higher 95th percentile (>78.96%) PC30 (HR 4.17) and reduced (>0.22) 
circularity (HR 3.94) represented the retained model variables. Not only were the 
DCE-MRI based retained model variables associated with higher hazard ratios than 
the retained traditional survival indicators, but the level of significance attached to the 
hazard ratios was also at a much higher level. Similar results were noted for the 
overall survival multivariate analysis with negative ER receptor status (HR 5.38), T3 
or higher clinical tumour stage (HR 4.30), and large (>9.8cm3) MR tumour volume 
(HR 3.58) again all were retained by the model in addition to higher (>0.71) 25th 
percentile AUC60 (HR 5.73).  
 
By utilising the retained variables from the overall survival analysis subjects were 
stratified into risk of death (high and low) within five years of initiation of NAC, for the 
110 individuals where all data (ER receptor status, T-stage, MR tumour volume, and 
25th percentile AUC60) was available. Resulting Kaplan-Meier plots are illustrated in 
Figure 2 while Table 7 presents the results of the risk stratification compared to 
subject outcome (alive or dead). Kaplan-Meier logrank test results revealed highly 
significant differences in mean survival intervals for all three risk groups (traditional: 
low risk 58.7 months (56.9 – 60.5), high risk 49.4 months (45.2 – 53.6), p=0.0005; 
DCE-MRI: low risk 58.5 months (56.4 – 60.5), high risk 48.2 months (43.7 – 52.8), 
p=0.0001; and combined: low risk 57.5 months (55.6 – 59.3), high risk 33.9 months 
(25.8 – 42.0), p<0.0001). Risk stratification based on either traditional or DCE-MRI 
survival indicators performed to a similar level. However, combined traditional and 
MR risk stratification resulted in the most significant difference in survival intervals 
between the low and high risk groups. 
  
Discussion 
The vast majority of LABC patients who die from their disease do not die due to their 
primary tumour but from the consequences of metastatic spread [28]. Since elevated 
levels of neoangiogenesis enhance the likelihood of metastatic spread [29] there is 
an opportunity to identify individuals at higher risk of metastatic spread, and 
subsequently shorter survival intervals, via biomarkers that reflect tumour driven 
neoangiogenesis. The ability to identify patients at higher risk of shorter survival 
intervals could facilitate individualised treatments whereby more aggressive 
treatments and/or increased surveillance could be justified. 
  
DCE-MRI has been proposed as such a biomarker since DCE-MRI vascular kinetics 
have been correlated with both micro-vessel density, perfusion and pro-angiogenic 
factors such as VEGF [6, 30]. Further, given the correlation with traditional 
prognostic indicators we hypothesise that both texture [21] and shape [22] obtained 
from DCE-MRI datasets will also be associated with survival intervals. 
 
Previous studies have demonstrated the potential of MR based metrics as a pre-
treatment imaging biomarker of longer term survival [8-12, 15, 16, 19]. Generally, 
shorter survival intervals are associated with larger enhancing tumours [8, 10, 11, 
15, 16, 19], type III enhancement curve [11], reduced mean transit time [12], 
elevated rates of signal enhancement [7, 9, 10, 19], high washout rates [7], large 
AUC values [10], and tumour surrounding stroma with high signal enhancement ratio 
[15]. 
 
This study has demonstrated via univariate Cox proportional hazards analysis that 
the risk of a shorter survival interval, both disease free and overall, is elevated in 
individuals with tumours displaying the following DCE-MRI based pre-treatment 
characteristics: large size (LD or volume); rapid, leptokurtic, positively skewed, 
heterogeneous enhancement [maximum enhancement achieved (EImax) and rate of 
enhancement (RT, PC30, and initial slope)]; large amounts of contrast agent 
delivered and retained by the tumour over 60 seconds (AUC60); elevated textural 
features (sum variance, sum entropy, cluster shade, cluster prominence) and 
complex lesion shape. Univariate analysis of traditional prognostic indicators 
available prior to NAC treatment revealed negative hormone receptor status (ER and 
PR), triple negative intrinsic subtype, large primary tumour (≥T3) and positive nodal 
status (≥N1) all to be associated with shorter survival intervals (DFS and OS). 
 
Interactions between pre-treatment MR and traditional prognostic indicators were 
considered via multivariate survival analysis. Oestrogen receptor status, T stage and 
MR volume were all retained by both DFS and OS models with the addition of AUC60 
for OS and PC30 and circularity for DFS. Although ER status and T stage were 
retained by the models a number of established traditional prognostic indicators such 
as nodal status, histological grade and HER2 status were not included in the final 
models. While higher, more significant hazard ratios were noted for MR parameters 
in the DFS model all retained variables were of a similar prognostic value for the OS 
analysis. For both disease free and overall survival models MR parameter provided 
independent prognostic information in addition to the traditional prognostic indicators. 
 
When considering the vascular kinetics the pixel-by-pixel nature of the analysis 
allowed for an assessment of lesion heterogeneity. Interestingly, in keeping with 
current thinking [30-35] the mean and median values were of little prognostic value 
with only mean and median AUC60 values demonstrating any significant univariate 
results. This presumably reflected the fact that given the heterogeneous nature of 
breast tumours, mean and median metrics do not sufficiently characterise the tumour 
[32,35]. Literature reports have highlighted that quantification of tumour 
heterogeneity is associated with grade, treatment response and prognosis [30-35]. 
Typically, poorer prognosis is associated with high levels of entropy, kurtosis, 
standard deviation and positive skewness [32, 34]. This heterogeneous signature of 
poor prognosis was observed for both vascular and texture parameters with rapid, 
leptokurtic, positively skewed, heterogeneous vascular kinetics in addition to textural 
features indicating heterogeneous enhancement (sum variance, sum entropy, cluster 
shade, cluster prominence) all being associated with shorter survival intervals in this 
work.  
The goal of identifying imaging biomarkers of longer term survival is to facilitate 
individualised treatments. By utilising the hazard ratios from the overall survival 
analysis, it was possible to stratify patients into low or high risk of death within 5 
years of the initiation of NAC treatment, for traditional, MR and combined prognostic 
indicators. Stratification based on traditional prognostic indicators and MR 
parameters, in isolation, performed to a similar level with around 5% of cases 
identified as low risk dying within 5 years of NAC and therefore considered 
undertreated. Whereas for the high risk group around 65% of cases were still alive at 
the end of 5 years and therefore represented an over-treated population. Overall 
prediction accuracy was 59.1% and 64.5% for traditional and MR parameters 
respectively. When traditional and MR prognostic indicators were combined the 
number of over-treated cases was dramatically reduced by over half to 30% at the 
expense of an increased undertreated population (10%). Nevertheless, the 
prediction accuracy was considerably higher at 86.4% than the traditional or MR risk 
stratification results. This result not only demonstrates the added prognostic value of 
pre-treatment DCE-MRI parameters to traditional survival indicators but also the 
potential usefulness of this approach for tailored therapies. 
A number of limitations are highlighted when considering this study. Firstly, this study 
represents a single centre retrospective analysis of 112 subjects and as such the 
results might not reflect the wider population. Further, the ability to implement the 
findings of this report might be restricted given the utilised image protocol. In 
particular, variable temporal resolution, a change in FOV, a change in contrast agent 
and the utilised contrast dose might all affect the generalisation of this study’s 
results. Secondly, while an attempt to avoid overparameterisation in the multivariate 
analysis was made the resulting models were close to the subjects per feature lower 
limit of 5 [35] (DFS 5 subjects/feature, OS 6 subjects/feature). Thirdly, given the 
retrospective nature of this study dichotomisation of MR parameters based on the 
Youden index may not be applicable to a wider population. Additionally, the results of 
the multivariate analysis were not validated on an independent cohort, consequently, 
the generalisation of the model is unknown. Finally, a number of papers [9, 12, 18, 
19] have reported that early (post 1st or 2nd NAC cycle) changes from pre-treatment 
MR parameter values hold prognostic value. Unfortunately, due to local clinical 
practice this early NAC MR data was not available for this cohort.  
In conclusion this study not only concurs with previous reports that DCE-MRI 
vascular kinetic and volume obtained prior to NAC treatment have prognostic value 
but also finds that pre-treatment DCE-MRI based texture and shape metrics are also 
associated with survival intervals. Further, multivariate analysis revealed that model 
retained DCE-MRI variables provide independent prognostic information 
complementing traditional survival indicators. Finally, treatment stratification based 
on multivariate model retained variables resulted in higher prediction accuracy when 
traditional and DCE-MRI parameters were combined. While these results require 
validation from a much larger population it seems that DCE-MRI parameters 
acquired even before the initiation of NAC treatment are associated with survival 
intervals and as such can help to appropriately stratify treatment. 
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Table 1 Pre-treatment lesion characteristics, clinical and treatment information 
Parameter Patients  Percentage 
Histological grade    
Grade I 10  8.9 
Grade II 45 40.2 
Grade III 53 47.3 
Missing 4  3.6 
Histological type   
NST 34  30.4 
Ductal 59  52.7 
Lobular 16  14.3 
Mucinous 1  0.9 
Missing 2 1.8 
Oestrogen receptor   
Negative 30 26.8 
Positive 80 71.4 
Missing 2 1.8 
Progesterone receptor   
Negative 51 45.5 
Positive 59 52.7 
Missing 2  1.8 
HER2   
Negative 94 83.9 
Positive 18 16.1 
Intrinsic type   
Luminal A 43 38.4 
Luminal B/HER2 negative 19 17.0 
Luminal B/HER2 positive 15 13.4 
HER2 positive 3 2.7 
Triple negative 27 24.1 
missing 5 4.5 
T stage   
≤T2 61 54.5 
≥T3 51 45.5 
Parameter Patients  Percentage 
N stage   
N0 73 65.2 
≥N1 39 34.8 
Age   
≤45 32 28.6 
>45 80 71.4 
NAC regime   
ECT 70 62.5 
ECTm 21 18.8 
NTT1 8 7.1 
NTT2 7 6.3 
EC 2 1.8 
NTT1m 1 0.9 
ECm 1 0.9 
DCm 1 0.9 
C 1 0.9 
Surgery post NAC   
Mastectomy 50 44.6 
Breast conserving surgery 62 55.4 
Adjuvant therapy   
Radiotherapy (Rx) 26 23.2 
Rx with Hx and/or Cx 86 76.8 
 
NAC regimes: 
ECT  epirubicin, cyclophosphamide and taxane 
NTT1 (Neo-tAnGo trial protocol) epirubicin and cyclophosphamide with paclitaxel 
NTT2 (Neo-tAnGo trial protocol) epirubicin and cyclophosphamide with paclitaxel + gemcitabine 
EC  Epirubicin and cyclophosphamide 
DC  Docetaxel and cyclophosphamide 
C Capecitabine 
Alteration (reduced number of cycles or dose) to intended NAC regime denoted by m 
 
Rx radiotherapy; Hx hormonal therapy; Cx chemotherapy 
HER2 (human epidermal growth factor receptor 2) 
  
Table 2 DFS and OS follow up intervals for critical and censored individuals 
Event n (%) Median (min.-max.) months 
DFS critical event 29 (26%) 20 (8 – 53) 
DFS censored 83 (74%) 60 (19 – 60) 
OS critical event 24 (21%) 26 (12 - 59) 
OS censored 88 (79%) 60 (19 – 60) 
 
 
  
Table 3 Significant traditional prognostic indicators univariate Cox proportional hazards model results 
Variable n Disease free survival Overall survival 
Hazard ratio 95% CI p value Hazard ratio 95% CI p value 
ER        
+ve 80 1.000   1.000   
-ve 30 3.687 1.730 – 7.855 0.001 3.746 1.650 – 8.501 0.002 
PR        
+ve 59 1.000   1.000   
-ve 51 2.751 1.235 – 6.128 0.013 3.168 1.302 – 3.168 0.011 
Intrinsic type        
All other 80 1.000   1.000   
Triple negative 27 3.451 1.620 – 7.349 0.001 3.389 1.494 – 7.689 0.003 
T stage        
≤T2 61 1.000   1.000   
≥T3 51 3.705 1.640 – 8.371 0.002 5.146 1.921 – 13.787 0.001 
N stage        
N0 73 1.000   1.000   
≥N1 39 2.804 1.346 – 5.843 0.006 3.560 1.555 – 8.151 0.003 
 
  
  
Table 4 Significant DCE-MRI based metric univariate Cox proportional hazards model results 
Variable n Disease free survival Variable n Overall survival 
Hazard ratio 95% CI p 
 
  Hazard 
 
95% CI p 
 Size     Size     
Longest dimension(≤50mm) 67 1.000   Longest dimension(≤50mm) 67 1.000   
Longest dimension(>50mm) 45 4.859 2.149 – 10.988 <0.001 Longest dimension(>50mm) 45 6.715 2.506 – 17.995 <0.001 
Volume(≤9.8cm3) 62 1.000   Volume(≤9.8cm3) 62 1.000   
Volume(>9.8cm3) 50 5.040 2.150 – 11.818 <0.001 Volume(>9.8cm3) 50 7.688 2.623 – 22.530 <0.001 
Vascular kinetics     Vascular kinetics     
     Tmax SD(≤72.54sec) 30 1.000   
     Tmax SD(>72.54sec) 82 4.335 1.019 – 18.438 0.047 
     EImax 5th percentile(≤1.16) 93 1.000   
     EImax 5th percentile(>1.16) 19 2.602 1.113 – 6.082 0.027 
     EImax 10th percentile(≤1.30) 92 1.000   
     EImax 10th percentile(>1.30) 20 2.413 1.032 – 5.638 0.042 
     EImax 25th percentile(≤1.49) 91 1.000   
     EImax 25th percentile(>1.49) 21 2.351 1.006 – 5.495 0.048 
EImax 95th percentile(≤1.87) 60 1.000        
EImax 95th percentile(>1.87) 52 2.166 1.023 -4.589 0.044      
EImax SD(≤0.48) 92 1.000        
EImax SD(>0.48) 20 3.102 1.079 – 8.918 0.032      
EImax kurtosis(≤0.74) 39 1.000        
EImax kurtosis(>0.74) 73 2.916 1.112 – 7.646 0.030      
     Rise time skew(≤2.07) 34 1.000   
     Rise time skew(>2.07) 78 3.370 1.005 – 11.302 0.049 
Rise time kurtosis(≤4.81) 25 1.000   Rise time kurtosis(≤5.30) 28 1.000   
Rise time kurtosis(>4.81) 87 4.502 1.070 – 18.936 0.040 Rise time kurtosis(>5.30) 84 8.773 1.184 – 64.980 0.034 
          
nMITR skew(≤1.64) 45 1.000        
nMITR skew(>1.64) 67 2.374 1.014 – 5.559 0.046      
PC30 95th percentile(≤78.96%) 58 1.000   PC30 95th percentile(≤78.96%) 58 1.000   
PC30 95th percentile(>78.96%) 54 2.445 1.136 – 5.262 0.022 PC30 95th percentile(>78.96%) 54 2.490 1.065 – 5.820 0.035 
PC30 SD(≤12.46%) 34 1.000        
PC30 SD(>12.46%) 78 3.102 1.079 – 8.918 0.036      
PC30 skew(>-0.12) 64 1.000        
PC30 skew(≤-0.12) 48 2.112 1.008 – 4.424 0.048      
Initial upslope 75th(≤2.31) 
 
84 1.000   Initial upslope 75th(≤2.31) 
 
84 1.000   
Initial upslope 75th(>2.31)  
 
28 2.194 1.035 -4.650 0.040 Initial upslope 75th(>2.31)  
 
28 2.487 1.103 – 5.607 0.028 
Initial upslope 90th(≤2.94)  
 
88 1.000   Initial upslope 90th(≤2.94)  
 
89 1.000   
Initial upslope 90th(>2.94)   
 
24 2.239 1.040 – 4.819 0.039 Initial upslope 90th(>2.94)   
 
23 2.646 1.157 – 6.053 0.021 
     Initial upslope 95th(≤2.89)   
 
79 1.000   
     Initial upslope 95th(>2.89)    
 
33 2.340 1.048 – 5.227 0.038 
Initial upslope SD(≤0.37) 24 1.000        
Initial upslope SD(>0.37) 88 4.236 1.007 – 17.819 0.049      
Final slope skew(>-1.02) 69 1.000        
Final slope skew(≤-1.02) 43 2.159 1.037 – 4.492 0.040      
Final slope kurtosis(≤4.50) 69 1.000        
Final slope kurtosis(>4.50) 43 2.159 1.037 – 4.492 0.040      
     AUC60 25th percentile(≤0.71) 96 1.000   
     AUC60 25th percentile(>0.71) 16 2.746 1.138 -6.627 0.025 
AUC60 90th percentile(≤1.23) 89 1.000   AUC60 90th percentile(≤1.23) 90 1.000   
AUC60 90th percentile(>1.23) 23 2.402 1.115 – 5.171 0.025 AUC60 90th percentile(>1.23) 22 2.843 1.243 – 6.505 0.013 
     AUC60 95th percentile(≤1.37) 92 1.000   
     AUC60 95th percentile(>1.37) 20 2.658 1.137 – 6.218 0.024 
AUC60 mean(≤0.77) 80 1.000   AUC60 mean(≤0.77) 80 1.000   
AUC60 mean(>0.77) 32 2.100 1.002 – 4.400 0.049 AUC60 mean(>0.77) 32 2.472 1.106 – 5.522 0.027 
     AUC60 median(≤0.77) 83 1.000   
     AUC60 median(>0.77) 29 2.257 1.002 – 5.084 0.049 
Texture     Texture     
f7, sum variance(≤73.21) 29 1.000   f7, sum variance(≤73.21) 29 1.000   
f7, sum variance(>73.21) 83 3.614 1.093 – 11.948 0.035 f7, sum variance(>73.21) 83 9.327 1.259 – 69.082 0.029 
f8, sum entropy(≤4.93) 53 1.000   f8, sum entropy(≤4.93) 53 1.000   
f8, sum entropy(>4.93) 59 4.173 1.698 – 10.260 0.002 f8, sum entropy(>4.93) 59 7.533 2.244 – 25.284 0.001 
f15, cluster shade(≤-51.00) 74 1.000   f15, cluster shade(≤-51.00) 74 1.000   
f15, cluster shade(>-51.00) 38 2.246 1.083 – 4.656 0.030 f15, cluster shade(>-51.00) 38 2.486 1.115 – 5.542 0.026 
f16, cluster(≤10206.74) 
 
29 1.000   f16, cluster(≤10295.75)  
 
39 1.000   
f16, cluster(≤10206.74)  
 
83 3.650 1.104 – 12.068 0.034 f16, cluster(>10295.75)   
 
73 4.381 1.306 – 14.695 0.017 
Shape     Shape     
Complexity(≤28.19) 44 1.000   Complexity(≤28.19) 44 1.000   
Complexity(>28.19) 68 4.806 1.671 – 13.819 0.004 Complexity(>28.19) 68 3.709 1.267 – 10.858 0.017 
Circularity(≤0.22) 45 1.000        
Circularity(>0.22) 67 2.904 1.182 – 7.134 0.020      
Convexity(>0.65) 76 1.000        
Convexity(≤0.65) 36 2.157 1.041 – 4.469 0.039      
 
 Bold p value indicates MR variables entered into multivariate analysis 
  
Table 5 Multivariate Cox’s proportional hazards model results for DFS 
Retained variable Hazard ratio Hazard ratio 95% CI p value 
ER(-ve) 2.078 0.923 – 4.680 0.077 
T stage(≥T3) 2.339 0.887 – 6.169 0.086 
MR volume(>9.8cm3) 4.933 1.827 – 13.317 0.002 
PC30 95th percentile(>78.96%) 4.173 1.640 – 10.621 0.003 
Circularity(>0.22) 3.942 1.451 – 10.710 0.007 
 
  
Table 6 Multivariate Cox’s proportional hazards model results for OS 
Retained variable Hazard ratio Hazard ratio 95% CI p value 
ER(-ve) 5.382 2.029 – 14.279 0.001 
T stage(≥T3) 4.303 1.491 – 12.416 0.007 
MR volume(>9.8cm3) 3.578 1.142 – 11.210 0.029 
AUC60 25th percentile(>0.71) 5.730 1.995 – 16.458 0.001 
 
  
Table 7 Risk of death within 5 years of NAC initiation compared to actual outcome 
Variable type Low risk High risk Overall accuracy 
 Alive Dead Under treated Alive Dead Over treated  
Traditional indicators 44 2 2/46 (4.3%) 43 21 43/64 (67.2%) 65/110 (59.1%) 
MR based 51 3 3/54 (5.6%) 36 20 36/56 (64.3%) 71/110 (64.5%) 
Combined traditional and MR 81 9 9/90 (10%) 6 14 6/20 (30%) 95/110 (86.4%) 
  
 
Figure Legends 
Figure 1  
Schematic of MR data processing. Initially tumour segmentation was undertaken for 
each lesion containing slice. Following tumour segmentation vascular, texture and 
shape parameters were derived from the DCE-MRI data. 
 
Figure 2 
Resulting Kaplan-Meier plots from risk stratification based on overall survival 
analysis hazard ratios for (from left to right) traditional survival indicators, MR based 
prognostic factors and combined (traditional and MR) survival metrics. Combination 
of ER(-ve) and T stage(≤T2) results in a 0 score for traditional survival indicators while 
MR volume(≤9.8cm3) and AUC60 25th percentile(≤0.71) results in a 0 score for MR survival 
indicators. 
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